Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
To drive appropriate and dependable critical process control requirements, Biogen explored several novel strategies to increase process and raw material control and optimize communication of data throughout the supply chain.
How ADC chemistry and manufacturing have evolved over the years, present the challenges this growth has created and describe how CDMOs are adapting to these changes to meet customer needs.
The aggressive performance demands of industrial microbiology have limited the conversion of traditional fermentation processes into single-use systems. In order to address the unique needs of microbial applications, single-use fermentors have been designed to meet the requirements of microbial fermentation instead of being modified from a cell culture bioreactor.
A collaborative study with a new customer with the objective of taking an existing, smaller preclinical E. coli process previously performed in stainless steel vessels and scaling it up quickly using the Thermo Scientific™ HyPerforma™ 300 L Single-Use Fermentor (S.U.F.)
Reproducible freezing and thawing is critical for successful cell therapies. GE Healthcare’s G. John Morris explains why.
An overview of Libbs product portfolio and how they benefit from Thermo Fisher Scientific services.
See how GE Healthcare products that are currently used in the cell processing workflow for cell therapy.
Leaders address how next generation processing will have a significant impact on how therapies are brought to market, delivering them to patients faster and more cost-effectively than ever before.
Watch experts discuss best practices that can help you manage supply chain risks.
Millipore offers a broad range of single-use equipment, custom designed with our experts to meet the challenging needs of ADC production.
Explore an approach to interpret the extractables data generated for single-use components used in biopharmaceutical processes by adopting the BPOG (BioPhorum Operations Group) protocol as a baseline testing strategy.
Current demand for sterile injectable drug product manufacturing is fed by multiple dynamics, and when the decision has been made to outsource there is a spectrum of options: niche CMOs with a sterile-injectable focus, large CMOs with end-to-end services for a variety of dosage forms, and one-stop-shops where both API and drug product manufacturing from development through commercialization can be supported.
Modular connectivity enabling greater efficiency.
A comprehensive service portfolio that uniquely combines the crucial steps of your developmental process: mAb solutions, linker, payload and the final conjugation – all from a single source.